Compare ASTS & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTS | SNN |
|---|---|---|
| Founded | 2019 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4B | 14.0B |
| IPO Year | N/A | 1999 |
| Metric | ASTS | SNN |
|---|---|---|
| Price | $74.03 | $33.44 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 4 |
| Target Price | ★ $59.37 | $32.83 |
| AVG Volume (30 Days) | ★ 10.6M | 476.9K |
| Earning Date | 11-10-2025 | 03-02-2026 |
| Dividend Yield | N/A | ★ 2.19% |
| EPS Growth | N/A | ★ 59.91 |
| EPS | N/A | ★ 0.56 |
| Revenue | $18,531,000.00 | ★ $5,944,000,000.00 |
| Revenue This Year | $1,223.27 | $7.78 |
| Revenue Next Year | $363.99 | $5.13 |
| P/E Ratio | ★ N/A | $29.10 |
| Revenue Growth | ★ 641.24 | 5.35 |
| 52 Week Low | $17.50 | $23.69 |
| 52 Week High | $102.79 | $38.79 |
| Indicator | ASTS | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 62.62 | 48.01 |
| Support Level | $52.20 | $32.68 |
| Resistance Level | $57.81 | $33.56 |
| Average True Range (ATR) | 5.09 | 0.41 |
| MACD | 2.14 | 0.14 |
| Stochastic Oscillator | 95.81 | 78.51 |
AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building a cellular broadband network in space to operate directly with standard, unmodified mobile devices, and off-the-shelf mobile phones based on extensive IP and patent portfolio. It has focused on eliminating the connectivity gaps faced by mobile subscribers. The Company's spaceMobile Service is being designed to provide cost-effective, high-speed Cellular Broadband services to end-users who are out of terrestrial cellular coverage using existing mobile devices.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.